PARK7/DJ1 antibody (ab4150)

Product Name 

PARK7/DJ1 antibody

Product type 

Primary antibodies

Description 

Goat polyclonal to PARK7/DJ1

Immunogen 

Synthetic peptide: C-AAQVKAPLVLKD, corresponding to C terminal amino acids 178-189 of Human PARK7/DJ1
(Peptide available as ab22993.)
BLAST 'C-AAQVKAPLVLKD' with or

Reacts with 

Hu, Ms

Predicted to react 
(species key)

Rat
(Due to sequence homology)

Tested applications 
(see key)

IP, WB

Abreviews 

Customer reviews (see key)

Read about Abreviews (Read all Abreviews)

Application notes 
(see key)

Recommended dilutions
WB: Use at a concentration of 0.5 - 1 µg/ml. Detects a band of approximately 20 kDa (predicted molecular weight: 20 kDa). Use RIPA extraction buffer.


Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.

Positive control 
(see definition)

WB: Jurkat lysate, HeLa whole cell lysate , 3T3 whole cell lysate

Cellular localization 

Cytoplasmic, Mitochondrial and Nuclear

Research areas 

Cancer >> Signal transduction >> G protein signaling >> Small G proteins >> Other
Chromatin and Nuclear Signaling >> Chromatin Binding Proteins >> DNA / RNA binding
Signal Transduction >> Signaling Pathway >> G Protein Signaling >> Small G Proteins >> Regulators
Neuroscience >> Neurology process >> Neurodegenerative disease >> Parkinson's disease >> Parkin / PARK

Relevance 

PARK7/DJ1 is a ubiquitously expressed protein involved in various cellular processes including cell proliferation, RNA-binding, and oxidative stress. The protein has been found to colocalize within a subset of pathologic tau inclusions in a diverse group of neurodegenerative disorders known as tauopathies (Rizzu et al. 2004). Defects in PARK7/DJ1 are the cause of autosomal recessive early-onset Parkinson's disease 7 (PARK7). Parkinson's disease (PD) is a complex, multifactorial disorder that typically manifests after the age of 50 years. The disease is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. PARK7 is characterized by onset before 40 years and slow progression. It has also been suggested that PARK7/DJ1 is a mitogen dependent oncogene product involved in Ras related signal transduction pathways.

Database links 

Raised in 

Goat

Clonality 

Polyclonal

Isotype 

IgG

Purity 

IgG fraction

Storage buffer 

Tris saline, 0.02% Na azide, pH7.3 with 0.5% BSA

Material safety datasheet (MSDS) for this product:
Sodium Azide MSDS

Purification notes 

Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.

Form 

Liquid

Concentration 

0.500 mg/ml

Storage instructions 

Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

See below for PARK7/DJ1 antibody images, references, products related to ab4150 and other tools.

PARK7/DJ1 antibody images:

References for PARK7/DJ1 antibody (ab4150)

  This product has been used in: (two most recent references)

Baulac S et al. Increased DJ-1 expression under oxidative stress and in Alzheimer's disease brains. Mol Neurodegener 4:12 (2009). PubMed: 19243613

Saito Y et al. Turning point in apoptosis/necrosis induced by hydrogen peroxide. Free Radic Res 40:619-30 (2006). PubMed: 16753840

See all 4 publication references for this product.


If you publish research using ab4150 please let us know so that we can cite the reference on this datasheet.

Customer reviews (feedback) regarding PARK7/DJ1 antibody

Customer FAQs regarding PARK7/DJ1 antibody

Protocols for PARK7/DJ1 antibody

Price and availability of products related to PARK7/DJ1 antibody

PARK7/DJ1 antibody - related products: